# Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer

> **NCT01495247** · PHASE1,PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 18 (actual)

## Conditions studied

- Inoperable Locally Advanced Breast Cancer
- Metastatic Breast Cancer (MBC)

## Interventions

- **DRUG:** BEZ235
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01495247
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-01-30
- **Primary completion:** 2014-05-19
- **Final completion:** 2014-05-19
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Study did not meet Phase Ib primary objective to establish the maximum tolerated dose/recommended dose for Phase II
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01495247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01495247, "Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01495247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*